A Phase IIa Study of the MEK Inhibitor GSK1120212 Monotherapy in the Treatment of Gemcitabine Refractory Locally Advanced, Recurrent or Metastatic Biliary Tract Cancers
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Trametinib (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 18 Aug 2016 Status changed from active, no longer recruiting to completed.
- 02 Mar 2016 Planned End Date changed from 1 Feb 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.